Table 2.
Change in characteristics at 1 year
| Dapagliflozin (N = 30) |
Placebo (N = 30) |
|
|---|---|---|
| LVEF (%) | 36.3 (0.54) | 33.7 (0.54) |
| Change from baseline | 5.5 (0.73) | 2.5 (0.71) |
| Difference vs. placebo | 2.5 (0.77) | |
| 95% CI | 1.00–4.06 | |
| P | 0.002 | |
| LVED volume (ml) | 169.3 (0.74) | 175.3 (0.74) |
| Change from baseline | −12.3 (3.07) | −3.3 (2.30) |
| Difference vs. placebo | −6.0 (1.05) | |
| 95% CI | −8.07 -−3.87 | |
| P | <0.001 | |
| LVES volume (ml) | 107.9 (1.04) | 116.1(1.04) |
| Change from baseline | −18.1 (2.66) | −6.7 (2.23) |
| Difference vs. placebo | −8.1 (1.48) | |
| 95% CI | −11.07 -−5.14 | |
| P | <0.001 | |
| LVED diameter (mm) | 53.8 (0.83) | 55.5 (0.36) |
| Change from baseline | −5.4 (0.83) | −4.4 (1.08) |
| Difference vs. placebo | −1.6 (0.51) | |
| 95% CI | −2.67 -−0.62 | |
| P | 0.002 | |
| LVES diameter (mm) | 46.0 (1.04) | 48.3 (1.04) |
| Change from baseline | −4.3 (1.58) | −2.4 (0.97) |
| Difference vs. placebo | −2.3 (1.47) | |
| 95% CI | −5.25 -−0.63 | |
| P | 0.121 | |
| VTI (cm) | 17.1 (0.07) | 16.9 (0.07) |
| Change from baseline | 0.79 (0.45) | 0.40 (0.50) |
| Difference vs. placebo | 0.20 (0.09) | |
| 95% CI | 0.01–0.38 | |
| P | 0.036 | |
| Cardiac index output (L/min/m2) | 2.9 (0.06) | 2.7 (0.06) |
| Change from baseline | 0.3 (0.06) | 0.2 (0.06) |
| Difference vs. placebo | 0.15 (0.08) | |
| 95% CI | −0.02–0.31 | |
| P | 0.076 | |
| Systolic pulmonary pressure (mmHg) | 23.2 (0.66) | 24.8 (0.66) |
| Change from baseline | −8.0 (1.15) | −7.1 (1.60) |
| Difference vs. placebo | −1.6 (0.93) | |
| 95% CI | −3.44–0.28 | |
| P | 0.094 | |
| HbA1c (%) | 7.3(0.05) | 7.9(0.05) |
| Change from baseline | −0.6(0.04) | −0.08(0.06) |
| Difference vs. placebo | −0.6(0.07) | |
| 95% CI | −0.702–0.437 | |
| P | < 0.001 |